The subcutaneous administration of granisetron, an antiemetic pharmaceutical drug (suitable for control of vomiting), achieves similar blood concentrations to those administered intravenously. This ...
Sandoz is offering treprostinil injection for subcutaneous administration to treat patients diagnosed with pulmonary arterial hypertension. Sandoz treprostinil injection was the first generic of ...
The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneous therapy for patients with epidermal growth ...
MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical ...
Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs. intravenously, U.S. facilities appear to underuse this delivery method, according to a research ...
First biologic available in both subcutaneous (SC) and intravenous (IV) formulations for the treatment of rheumatoid arthritis Subcutaneous ORENCIA demonstrated similar efficacy (non-inferior for ...
- Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with ...
The gastric hormone ghrelin appears a useful agent to stimulate food intake in people with anorexia of illness. The loss of ghrelin's acyl group renders it inactive, thus it has been thought that ...
The market for Subcutaneous Drug Delivery Devices was valued at US$ 23 billion in 2021, and between 2023 to 2032, it is expected to grow at a CAGR of 11%. Drug administration through the subcutaneous ...